This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BEREZIN, M. Articles by LUNENFELD, B. Search for Related Content PubMed PubMed Citation Articles by BEREZIN, M. Articles by LUNENFELD, B.

Reduction of Follicle-Stimulating Hormone (FSH) Secretion in FSH-Producing Pituitary Adenoma by Bromocriptine

Institute of Endocrinology The Chaim Sheba Medical Center, Tel-Hashomer, 52621 Israel, and Tel-Aviv University Sackler School of Medicine, Tel-Aviv, Israel
Section of Diagnostic Neuroradiology of The Department of Radiology The Chaim Sheba Medical Center, Tel-Hashomer, 52621 Israel, and Tel-Aviv University Sackler School of Medicine, Tel-Aviv, Israel

Address correspondence and requests for reprints to: M. Berezin, M.D., Institute of Endocrinology, The Chaim Sheba Medical Center, Tel Hashomer, 52621 Israel.

An FSH-secreting pituitary adenoma was demonstrated in a 32-yr-old man who presented with unilateral optic atrophy without any clinical or laboratory evidence of hypogonadism. Semen analysis was normal, although basal FSH levels were markedly elevated (>80 mlU/ml). He had normal plasma LH levels and no other detectable endocrine abnormalities. Administration of GnRH elicited delayed and sustained FSH and brisk LH responses. Administration of TRH resulted in TSH and PRL responses and unexpected FSH and LH elevations. Two surgical operations resulted in temporary reduction of plasma FSH levels, but it increased later concomitant with CT demonstration of tumor growth. After pituitary irradiation, no reduction in FSH levels occurred. A single dose of 5 mg bromocriptine elicited a significant reduction in FSH levels from 137 to 64 mlU/ml. Long term treatment with 15 mg/day bromocriptine resulted in further reduction of FSH level, to 36.4 mlU/ml, without any change in tumor size. This finding implies that bromocriptine could be an adjunctive therapy or an alternative to other modes of treatment in patients with these rare tumors.

Received March 9, 1984.

This article has been cited by other articles:

				Y. Murata, H. Ando, T. Nagasaka, I. Takahashi, K. Saito, H. Fukugaki, K. Matsuzawa, and S. Mizutani Successful Pregnancy after Bromocriptine Therapy in an Anovulatory Woman Complicated with Ovarian Hyperstimulation Caused by Follicle-Stimulating Hormone-Producing Plurihormonal Pituitary Microadenoma J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1988 - 1993. [Abstract] [Full Text] [PDF]

				I. Shimon, T. Rubinek, I. Bar-Hava, D. Nass, M. Hadani, A. Amsterdam, and G. Harel Ovarian Hyperstimulation without Elevated Serum Estradiol Associated with Pure Follicle-Stimulating Hormone-Secreting Pituitary Adenoma J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3635 - 3640. [Abstract] [Full Text] [PDF]